According to the report, several key dietary behaviors such as daily fruit or vegetable intake among high school students were trending in the wrong direction. The Centers for Disease Control and ...

Of those with a minimum age or minimum interval vaccine dose, 44.9% ended up receiving extra doses to complete a vaccination series. Vaccine doses provided to children outside of the CDC's Advisory ...

The lead clinical trial investigator for a phase 3 study of crinecerfont in pediatric CAH patients breaks down the December 2024 FDA approval. The FDA approval of crinecerfont (Crenessity; Neurocrine ...

The REACH Institute awards 50 cognitive behavioral therapy (CBT) scholarships to primary care clinicians nationwide to bridge critical gaps in pediatric mental health care ...

Principal investigator Lewis Romer, MD, of Johns Hopkins Medicine joined us to discuss the actively-recruiting MoD PAH trial assessing mono vs dual therapy for pediatric PAH. Lewis Romer, MD, ...

Neffy was first approved in September 2024 to treat type 1 allergic reactions in patients who weigh at least 66 lbs (33 kg). ARS Pharmaceuticals has announced new developments for neffy (epinephrine ...

Results from a recent study revealed that compulsive and addictive elements can contribute to the risk of disordered eating. Study investigator Susan Carnell, PhD, explains these findings. Carnell is ...

Positive interim data was reported from the ENERGY 1 trial and Expanded Access Program that featured a total of 5 infants and 1 child. Positive interim data from Inozyme Pharma has been reported for ...

Lifestyle medicine and mental health management in pediatric primary care promote positive health and holistic well-being. Psychopharmacologic agents used in the pediatric population from the ...

Lifestyle medicine and mental health management in pediatric primary care promote positive health and holistic well-being.

In an open-label extension of the EPITOPE phase 3 trial, the Viaskin Peanut patch had continued improvement in toddlers aged 1-3 years through 36 months. Positive data from an open-label extension ...